Maven Securities’s CorMedix CRMD Stock Holding History

Maven Securities’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-111,065	Closed	-$1.08M	–	1105
2021 Q1	$1.08M	Buy	+111,065	New	+$1.17M	0.05%	382

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Maven Securities's CRMD Position: Q2 2021 in Review

Maven Securities sold out of CorMedix (CRMD) in Q2 2021, closing a stake of 111,065 shares — an estimated $1.08M sold.

Maven Securities first reported a position in CRMD in Q1 2021 and held it in 1 quarter. The position peaked at $1.08M in Q1 2021. 79 funds tracked by Wall St. Rank hold CRMD as of Q2 2021.

Maven Securities reported no remaining CorMedix position as of Q2 2021 after selling out during the quarter.
Maven Securities sold 111,065 CorMedix shares in Q2 2021, an estimated $1.08M.
Maven Securities first reported a position in CorMedix in Q1 2021 and held it in 1 quarter.
Maven Securities's CorMedix position peaked at $1.08M in Q1 2021.
79 funds tracked by Wall St. Rank held CorMedix as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.